XL Mont Syrup is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg per 5 ml, formulated for the management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), reducing airway inflammation and bronchoconstriction commonly observed in asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from both upper and lower respiratory allergic manifestations. XL Mont Syrup is indicated for pediatric patients requiring effective symptom control of allergic rhinitis, chronic urticaria, and mild to moderate asthma. The syrup formulation ensures ease of administration and accurate dosing in children. It is generally well tolerated; however, potential side effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment or hypersensitivity to any component. XL Mont Syrup should be used under medical supervision, with adherence to prescribed dosage to optimize therapeutic outcomes and minimize adverse effects.